Using a scalp device plus temozolomide for brainstem gliomas
Part of Cancer clinical trials.
This study tests whether Tumor Treating Fields (a wearable electrical device placed on the scalp) combined with temozolomide can treat brainstem gliomas (tumors in key parts of the brainstem). It may help slow tumor growth and improve outcomes for adults who have already finished surgery/radiation or are otherwise ready for the next treatment step.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a glioma that involves or invades parts of the brainstem (like the pons, midbrain, or thalamus area)
- You finished all prior cancer treatment (including surgery and radiation) at least 4 weeks ago
- You can do study visits and required tests, and follow the treatment plan
- Your basic blood and organ tests are strong enough for treatment with temozolomide
- You agree to use effective birth control during the study (and for a while after), if you can become pregnant or if you are a male partner
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
This trial tests an experimental drug called NLG802 combined with the chemotherapy drug temozolomide for children and young adults whose brain or spinal cancer has come back or has not responded to treatment. The goal is to see if this combination can help shrink tumors or slow their growth.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial tests whether adding the Optune device (a wearable electric field therapy) to standard chemotherapy (temozolomide) and the immunotherapy drug pembrolizumab can help people with newly diagnosed glioblastoma live longer. You may be able to join if you've completed initial radiation and chemo, and have not received certain immunotherapies before.
This trial tests whether wearing a device called Optune (which uses electric fields to slow cancer growth) before surgery helps people with glioblastoma. It is for patients who are fairly active and plan to have standard tumor removal and radiation therapy afterward.
This trial tests whether adding sonodynamic therapy (a treatment that uses sound waves to activate a drug) before standard radiation and chemotherapy can help people with a type of brainstem glioma called DIPG. The goal is to see if this combination improves survival.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.